← All companies
$9.01
−1.21% (−$0.11) on the day
Close Nov 13, 2026
Market cap
$1.28B
1 month
−22.46%
52-week range
$4.88–$15.87
Last month
Why we cover it
Developer of COMP360, a synthetic psilocybin formulation for treatment-resistant depression. After two positive Phase 3 trials, Compass submitted its application to the FDA in November 2026, making psilocybin one of the psychedelic drugs now under FDA review.
Financials
| Cash & equivalents | $444M | as of Sep 30, 2026 · 10-Q |
| Research & development | $23.5M | quarter ended Sep 30, 2026 · 10-Q |
| Net income (loss) | −$9.83M | quarter ended Sep 30, 2026 · 10-Q |
From the company's SEC filings. See all filings ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| COMP360 for Treatment-Resistant Depression | Psilocybin | NDA submitted to FDA (Nov. 9, 2026) |
Patents Patent tracker
| Holder | Compounds | Granted | Pending | Expire |
|---|---|---|---|---|
| Compass Pathfinder Limited | Psilocybin, LSD | 13 | 21 | 2039–2044 |
News (8)
- Nov 15, 2026 A Trade-Secrets Fight Over Psilocybin Research Is Headed to Trial, as Compass Awaits the FDA
- Nov 10, 2026 Compass Files for FDA Approval of Psilocybin, a Week Early. Three Psychedelic Drugs Are Now Under Review.
- Nov 6, 2026 What We're Watching: Compass's Filing Clock, Definium's First Call Since Its Rally, and the Ibogaine Deadline
- Nov 5, 2026 Runway Extended: Compass Banks $444M Into 2028 as Its Psilocybin NDA Nears the Finish Line
- Nov 2, 2026 Usona Files Its Psilocybin NDA for Depression, Tightening the Race With Compass
- Oct 28, 2026 Eli Lilly's Carole Ho Says 5-MeO-DMT "Fits the Spravato Model" as Investors Call Pharma "Cash Rich and Pipeline Poor"
- Aug 20, 2026 New on Altitude: Who Actually Holds Psilocybin's 223 Patents
- Jul 7, 2026 Compass Pathways' Psilocybin Benefit Held Up at 26 Weeks — And Retreatment Helped More
In the Journal (20)
- Nov 12, 2026 One Dose, Years of Relief? What Psilocybin Trials Found in People With Cancer
- Nov 12, 2026 How Long Does Relief Last? Antidepressants vs. Psychedelics, by the Numbers
- Nov 11, 2026 Altitude People Series, Week 3 — Business: The Billionaire Who Built a Psychedelics Company on One Mushroom Trip
- Nov 9, 2026 The Day After Approval: Which States Will Let Doctors Prescribe Psilocybin
- Nov 7, 2026 After the Election, the Fights Move Indoors: ICER, a Courtroom and a New Drug Law for Psilocybin
- Oct 1, 2026 Meet the 7 People Who Actually Lobby for Psychedelics in Washington
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 26, 2026 150+ Patents, $113 Million Raised, 4 Employees: Inside the Company Betting It Doesn't Need to Run Its Own Trials
- Sep 26, 2026 16 States, 7 New Laws, 11 Dead Bills, Only 2 Still Alive: We Scored the 2026 Psychedelic Legislative Session
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 22, 2026 How Clinical Trials Actually Work — and What It Means for the Psychedelic Industry
- Sep 21, 2026 19% of American Adults Have Anxiety. Every Drug Treating It Is a Decades-Old Generic — Here's Who Wins If DT120 Changes That
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.